Cargando…

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

Clinical resistance to the second-generation antiandrogen enzalutamide in castration resistant prostate cancer (CRPC), despite persistent androgen receptor (AR) activity in tumors, highlights the unmet medical need for next generation antagonists. We have identified and characterized tetra-aryl cycl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pollock, Julie A., Wardell, Suzanne E., Parent, Alexander A., Stagg, David B., Ellison, Stephanie J., Alley, Holly M., Chao, Christina A., Lawrence, Scott A., Stice, James P., Spasojevic, Ivan, Baker, Jennifer G., Kim, Sung Hoon, McDonnell, Donald P., Katzenellenbogen, John A., Norris, John D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030124/ https://www.ncbi.nlm.nih.gov/pubmed/27501397 http://dx.doi.org/10.1038/nchembio.2131

Ejemplares similares

Targeting mutant estrogen receptors
por: Wardell, Suzanne E, et al.
Publicado: (2019)

Single-step purification of full-length human androgen receptor
por: Juzumiene, Dalia, et al.
Publicado: (2005)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging
por: Katzenellenbogen, John A.
Publicado: (2020)

Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis in an androgen-sensitive rat prostatic adenocarcinoma.
por: Westin, P., et al.
Publicado: (1995)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
por: Wardell, Suzanne E., et al.
Publicado: (2019)

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
por: Wardell, Suzanne E., et al.
Publicado: (2019)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer
por: Titus, Mark A., et al.
Publicado: (2012)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
por: Gunter, Jennifer H., et al.
Publicado: (2012)

π–π Interaction Energies as Determinants of the Photodimerization of Mono-, Di-, and Triazastilbenes
por: Parent, Alexander A., et al.
Publicado: (2014)

11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration
por: Snaterse, Gido, et al.
Publicado: (2021)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer
por: Zardan, A, et al.
Publicado: (2014)

Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting
por: Sawant, Mithila, et al.
Publicado: (2022)

Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment
por: Fiandalo, Michael V., et al.
Publicado: (2014)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
por: Ban, Fuqiang, et al.
Publicado: (2021)

The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens
por: Schweizer, Liang, et al.
Publicado: (2008)

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling
por: Nguyen, Holly M., et al.
Publicado: (2013)

Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
por: Kokontis, John M., et al.
Publicado: (2014)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Castration delays epigenetic aging and feminizes DNA methylation at androgen-regulated loci
por: Sugrue, Victoria J, et al.
Publicado: (2021)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats
por: Liu, Rong-Fu, et al.
Publicado: (2018)

Predicting castration-resistant prostate cancer after combined androgen blockade
por: He, Miao, et al.
Publicado: (2017)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

How do we define “castration” in men on androgen deprivation therapy?
por: Itty, Sarin, et al.
Publicado: (2020)

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022)

Small Molecule Antagonists of the Nuclear Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer
por: Johnson, James K., et al.
Publicado: (2016)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_28kpuos8qd72k5490kttor4jcc